CMP Pharma, Inc Announces that Atorvaliq®, the First and Only FDA-approved Liquid Suspension of Atorvastatin is Now Available
FARMVILLE, N.C., June 23, 2023 /PRNewswire/ -- CMP Pharma, Inc. announced today that Atorvaliq (atorvastatin calcium) Oral Suspension, 20 mg/5 mL, the first and only FDA-approved oral liquid of atorvastatin, is now available.
Atorvaliq is a ready-made liquid oral suspension of atorvastatin approved for patients 10 years of age and older. Atorvaliq is indicated for the treatment of high cholesterol and certain risk factors for heart disease or stroke.
FDA-approved Atorvaliq does not require special preparation and does not require refrigeration. Atorvaliq comes in a pleasant tasting citrus orange-flavored suspension and is available in a 150 mL bottle with a 24-month shelf. Atorvaliq offers convenience and addresses inconsistencies that may exist with unapproved crushed or compounded tablet formulations.
"Atorvaliq is intended for a subset of the patient population that needs atorvastatin but has dysphagia or difficulty swallowing tablets. The availability of Atorvaliq gives healthcare providers and appropriate patients a convenient, safe, and FDA-approved liquid formulation," said Gerald Sakowski, CEO of CMP Pharma, Inc.
Atorvaliq (atorvastatin calcium) Oral Suspension is now available. For more information, contact CMP Pharma at 252-753-7111 or visit atorvaliq.com.
About CMP Pharma, Inc. CMP Pharma is a specialty pharmaceutical company that addresses critical needs for niche markets by developing and manufacturing a portfolio of high value pharmaceutical products, including oral liquids and semi-solids. CMP Pharma combines decades of experience in pharmaceutical development and manufacturing to provide medicines to fill the unmet medical needs of many patients.
Important Safety Information Indications and Usage ATORVALIQ is indicated:
To reduce the risk of:
Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD.
MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD.
Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD.
As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia and adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
As an adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
As an adjunct to diet for the treatment of adults with primary dysbetalipoproteinemia or hypertriglyceridemia.
Contraindications
Acute liver failure or decompensated cirrhosis.
Hypersensitivity to atorvastatin or any excipients in ATORVALIQ.
Warnings and Precautions
Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher ATORVALIQ dosage. Discontinue ATORVALIQ if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue ATORVALIQ in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing ATORVALIQ dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.
Immune-Mediated Necrotizing Myopathy (IMNM): Rare reports of IMNM, an autoimmune myopathy, have been reported with statin use. Discontinue ATORVALIQ if IMNM is suspected.
Hepatic Dysfunction: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue ATORVALIQ.
Adverse Reactions
Most common adverse reactions (incidence ? 5%) are nasopharyngitis, arthralgia, diarrhea, pain in the extremity, and urinary tract infection.
To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interactions
See full prescribing information for details regarding concomitant use of ATORVALIQ with other drugs or grapefruit juice that increase the risk of myopathy and rhabdomyolysis.
Rifampin: May reduce atorvastatin plasma concentrations. Administer simultaneously with ATORVALIQ.
Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive.
Digoxin: May increase digoxin plasma levels; monitor patients appropriately.
See full prescribing information for ATORVALIQ dosage modifications due to drug interactions.
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective...
Marc Dubrick and Lisa Becharas are bringing victories home to Boulder, Colorado, after winning their first St. Anthony's Triathlon along St. Petersburg's scenic downtown waterfront. The winners, who are teammates on The Real Triathlon Squad, raced a...
Nicholas Baker, M.D., Director of Robotic Thoracic Surgery at the University of Pittsburgh Medical Center (UPMC) Passavant, presented key findings from independent research at the 104th Annual Meeting of the American Association for Thoracic Surgery...
Sexton Lawn & Landscapes is thrilled to announce the appointment of Brooks Breland as the leading Lawn and Plant Health Expert. In this role, Breland will...
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9...